Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine by Norrby, Erling
HISTORICAL FEATURE
JEM © The Rockefeller University Press  $30.00
Vol. 204, No. 12,  November 26, 2007  2779–2784  www.jem.org/cgi/doi/10.1084/jem.20072290
2779
Yellow fever and Max Theiler: the only Nobel Prize 
for a virus vaccine
In 1951, Max Theiler of the Rockefeller Foundation received the Nobel Prize 
in Physiology or Medicine for his discovery of an effective vaccine against 
yellow fever—a discovery first reported in the JEM 70 years ago. This was the 
first, and so far the only, Nobel Prize given for the development of a virus 
vaccine. Recently released Nobel archives now reveal how the advances in 
the yellow fever vaccine field were evaluated more than 50 years ago, and 
how this led to a prize for Max Theiler.
Yellow fever disease has caused life-
threatening epidemics throughout the 
last 500 years of human civilization. In 
the first half of the 20th century, the 
viral origin of the disease was identi-
fied, its means of spreading was clari-
fied, and possible ways to prevent it 
were found. The concluding advance 
in these studies was Max Theiler’s de-
velopment of the 17D strain of attenu-
ated virus, first reported in this Journal 
(1), which could be used as a live vac-
cine to save the lives of many millions 
of people. There was no question that 
the introduction of this vaccine was “to 
the benefit of mankind,” as specified in 
Alfred Nobel’s will, but how does 
Theiler’s contribution compare with 
other advances that lead to vaccines 
against viral diseases that were intro-
duced both earlier and later?
The aim of this article is to discuss 
the recently released Nobel archives to 
show how the advances in the yellow 
fever vaccine field were evaluated more 
than 50 years ago, and how this led to 
a prize for Max Theiler. The article will 
also discuss why the yellow fever vac-
cine has been singled out as the only 
viral vaccine hitherto recognized by a 
Nobel Prize, and the concept of “dis-
covery,” which was specified by Nobel 
as the one and only criterion of a prize 
in physiology or medicine.
The disease and the epidemics
Yellow fever is an infectious disease 
that leads to damage of many organs in 
the body, frequently due to severe 
bleeding. The liver is often affected, 
which eventually leads to jaundice, the 
symptom that gave the disease its name. 
For many hundreds of years, dreadful 
epidemics of yellow fever afflicted 
densely populated areas in countries 
with warmer climates. The way the 
disease spread remained enigmatic for 
centuries, and there were no means 
for rational intervention. This situation 
changed in 1900, when a commission 
headed by United States Army Surgeon 
Walter Reed used human volunteers 
to show that a mosquito vector, Aedes 
aegypti, was critical in the dissemination 
of the disease.
In 1915, a Yellow Fever Commis-
sion was established by the Interna-
tional Health Board, which was funded 
by the Rockefeller Foundation, with 
the primary goal of eliminating breed-
ing places for Aedes aegypti in areas 
where yellow fever was prevalent. This 
eradication effort was highly effective 
in many cases. In some settings, how-
ever, the disease remained, and this 
was not explained until the mid-1930s 
when new techniques were developed to 
study the virus and immunity against it. 
It then became clear that the natural 
reservoir of the virus was monkeys, be-
tween which the infection was spread 
by various jungle-dwelling mosquitoes. 
The virus was occasionally transmitted 
from infected monkeys to humans by a 
range of different vectors, resulting in 
individual or small clusters of cases. If, 
however, these spurious cases of yellow 
fever (known as jungle or sylvan yellow 
fever) contacted larger human popula-
tions in urban areas, severe epidemics 
could develop in which the virus was 
then transmitted by Aedes aegypti from 
man to man.
With the development of a safe and 
effective vaccine by Theiler in 1937 
(1–5), the urban form of the disease was 
eliminated, but epidemics of the jungle 
form of the illness still occur in the 
tropical belts of the Americas and 
  Africa. It is estimated that approximately 
200,000 cases and 30,000 deaths occur 
every year in nonimmunized popula-
tions. Much has been learned during the 
last 50 years about the complex inter-
actions between different hosts, various 
mosquito vectors and strains of the virus, 
and the need for continued vaccination 
in certain settings (6).
The virus and possibilities for vaccine 
development
The Walter Reed Commission showed 
in 1902 that the agent that causes yellow 
fever passed through bacteria-proof 
filters (7). This was the first human infec-
tious agent shown to be ultra-filterable, 
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When Theiler arrived at The Rockefeller 
Institute in 1930, it was already the 
world’s most important center of 
experimental yellow fever research.
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but it took time before the scientific 
community was convinced that the 
agent was truly a virus. Adrian Stokes 
and collaborators at the Rockefeller 
Foundation laboratory in Nigeria 
showed in 1927 that monkeys could be 
infected with material from humans 
with yellow fever (8). This was an im-
portant breakthrough, as the viral nature 
of the agent was confirmed using this 
animal system. The isolated virus was 
named the Asibi strain after the 28-
year-old West African yellow fever 
survivor who provided the blood sample. 
This virus strain came to play a central 
role in the eventual development of a 
successful vaccine.
When Theiler arrived at The 
Rockefeller Institute in New York in 
1930, it was already the world’s most 
important center of experimental yellow 
fever research. Conditions for experi-
menting with monkeys had been estab-
lished, and the basic properties of the 
virus had already been analyzed. Yellow 
fever virus turned out to be a relatively 
small virus (9). It readily lost its infec-
tivity, but the presence of proteins 
stabilized this property. In present-day 
classification (10), the yellow fever virus 
is grouped together with more than 80 
other viruses carried by arthropod vectors. 
The group is named flavivirus, from the 
Latin flavus meaning yellow, a collective 
name appropriately derived from its most 
prominent member.
Max Theiler, the experimental scientist
Those who met Theiler give the same 
description of him as an exceptionally 
modest, gentle, and unassuming person. 
He was born in Pretoria, South Africa, 
in 1899 of Swiss-born parents and spent 
the first 20 years of his life there. After 
premedical training in South Africa, 
he went to England to do his medical 
training at St Thomas’ Hospital in 
London. In 1922, he became a Licentiate 
of the Royal College of Physicians and 
a member of the Royal College of 
Surgeons, and in the same year he 
was  awarded a Diploma of Tropical 
Medicine and Hygiene. Later that year, 
he went to the United States where he 
became first an assistant and later an 
instructor at the Department of   Tropical 
Medicine at Harvard Medical School 
(Boston, MA).
The head of  the department, Andrew 
Watson Sellards, had a particular inter-
est in yellow fever. Following the suc-
cess of the researchers at Rockefeller 
foundation, he and his collaborators—
then working in Dakar, French West 
Africa—had isolated the virus in mon-
keys (11). Sellards brought this isolate, 
called the French strain, to his laboratory 
in the United States. In his early work 
at Harvard, Theiler showed that the 
spirochete Leptospira icteroides had no in-
volvement in yellow fever (12). Although 
the Reed commission had already doc-
umented that the etiological agent of the 
disease was a virus, a theory that this spi-
rochete was involved had been persua-
sively argued by Hideyo Noguchi (13). 
Theiler’s findings conclusively disproved 
this. Theiler also did some preliminary 
comparative immunological studies of 
yellow fever viruses from West Africa and 
South America (14).
Theiler then propagated the French 
strain of virus in the brains of mice 
(15, 16). This was an important finding 
because it offered an alternative to the 
expensive and cumbersome use of mon-
keys to study the virus. Because of this 
contribution, the Rockefeller Foundation 
welcomed Theiler when he applied for 
a position in its International Health 
Division (formerly the International 
Health Board) in 1930. Theiler enjoyed 
the environment of the Foundation 
and remained associated with it until he 
retired in 1964. He died in 1972.
Theiler’s path of discovery
After Theiler’s 1930 discovery that yel-
low fever virus can be propagated by 
passage in the mouse brain, he found 
that repeated passages in mice led to a 
progressive shortening of the incuba-
tion time and, importantly, a successive 
reduction of the pathogenicity of the 
virus in monkeys. Theiler then devel-
oped a convenient test for measuring 
protective antibodies in mice (17). The 
technique also allowed a quantitative 
demonstration of the presence of anti-
bodies in humans. This proved to be an 
important tool for mapping the epide-
miology of infections and evaluating 
candidate vaccines. After Theiler’s work 
on yellow fever, mice came into wide-
spread use for studies of viruses that 
affect humans and animals.
The stage was now set for a full attack 
on the problem of establishing a stable, 
effective, and safe attenuated virus.
Asibi, West African yellow fever survivor, 
who provided a blood sample from which 
the virus, used in extensive future research, 
was isolated. Photo from reference 2.
Albert Sabin, the father of the live polio 
vaccine, who gave the only comprehensive 
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1948. Photo kindly provided by Samuel Katz.JEM VOL. 204, November 26, 2007  2781
HISTORICAL FEATURE
During the 1930s, Theiler tried to 
grow the virus in tissue cultures. To-
gether with Eugen Haagen, he eventu-
ally demonstrated the growth of mouse 
brain–adapted virus in chicken embryo 
cultures (18, 19). The stage was now set 
for a full attack on the problem of es-
tablishing a stable, effective, and safe 
attenuated virus. Theiler and collabora-
tors first demonstrated that the atten-
uation of virus obtained by passages in 
mice was not sufficient. This dimin-
ished the viscerotropic properties of the 
virus, which are the main source of the 
symptoms associated with yellow fever, 
but the capacity of the virus to attack 
the brain increased. To get around this 
problem, attempts were made to use 
minimal doses of virus, but this approach 
also failed. Theiler and Whitman dem-
onstrated that, paradoxically, lower doses 
of virus gave a higher frequency of 
encephalitis in monkeys (20, 21).
The critical experiments that solved 
this problem were performed by Theiler 
and his collaborators during 1935–1937 
(1, 22, 23). Different virus strains with 
various properties were carried through 
several hundred passages in different 
kinds of tissue cultures and repeatedly 
tested for their neurotrophic activity. 
The breakthrough came when the Asibi 
strain of virus—the first ever isolated—
was passed repeatedly in minced chicken 
embryos from which the central nervous 
system had been removed. Between the 
89th and 114th passage, a virus variant 
suddenly emerged that lacked both the 
viscerotrophic and the neurotropic effects 
(1). Fortunately, the properties of this 
virus were stable, and its neurovirulence 
was not regained upon repeated passages 
in chicken embryo cultures containing 
brain material.
The first field trial with the new 
vaccine, started under the aegis of the 
Rockefeller Foundation in Brazil in 
1938, was highly successful. And the 
continued use of more than 400 million 
doses for over 60 years of the 17D virus 
vaccine has proven it to be a remarkably 
safe and effective product. The World 
Health Organization guidelines regarding 
the vaccine have remained unchanged 
(24). Today, the vaccine is still produced 
using the original methods: it is passaged 
in embryonated chicken eggs and stored 
as a frozen homogenate.
The first deliberation by the Nobel 
Committee
The Nobel archives remain closed to 
researchers for 50 years, and hence the 
files on Theiler have only recently be-
come available (25). Three kinds of 
material can be examined: the submit-
ted nominations, the reviews made by 
professors of Karolinska Institutet, and 
the recommendations by the Nobel 
Committee for Physiology or Medicine 
to the College of Teachers. Candidates 
considered to be prize-worthy were 
listed, and the candidate(s) recommended 
for the prize by the majority of the com-
mittee was presented without any com-
ments on the basis of the committee’s 
decision.
To be considered for a Nobel Prize 
in a certain year, an individual must be 
nominated before January 31 of that 
year (26). Max Theiler was first nomi-
nated for the Nobel Prize in Physiol-
ogy or Medicine in 1937 by Friedrich 
K. Kleine of the Robert Koch Institute 
for Infectious Diseases (Berlin, Germany) 
for his work on yellow fever in mice. 
These findings, however, were not in-
terpreted by the committee to have 
sufficient originality to motivate further 
consideration of Theiler for the Prize. 
The next nomination came in 1948, with 
the development of the yellow fever 
vaccine as the core of the proposal. 
The nominator in 1948 was Albert 
Sabin, a respected authority in patho-
genesis of viral diseases who could well 
appreciate the challenge of establishing 
an attenuated strain of virus to be used 
as a vaccine. Sabin had also worked at 
the Rockefeller Institute for Medical 
Research between 1935 and 1939 and, 
being at the same campus, had first-
hand insight into the critical advances 
made in Theiler’s laboratory. Later, Sabin 
became the father of the live polio 
vaccine that has successfully eliminated 
polio from many parts of the world.
Sabin’s nomination was very detailed, 
covering some six pages, and included 
reprints of Theiler’s most important 
papers. The Nobel Committee was seem-
ingly impressed by the nomination and 
asked Sven Gard (my former mentor), 
who had become professor of virus re-
search at the institute  the same year, to 
make a preliminary investigation. Gard, 
who would later become a pioneer in 
polio vaccine research, was highly qual-
ified to make such an evaluation. He 
knew Theiler’s work well from the 10 
months he spent in his laboratory in 
1939 as a visiting scholar, during which 
they worked on a mouse poliomyelitis–
like virus called Theiler’s virus (27, 28).
After an exhaustive preliminary re-
view, Gard concluded that Theiler’s 
work would be prize-worthy if a fur-
ther investigation showed that it was 
Theiler, and not Wray Lloyd, Theiler’s 
close friend and colleague who died 
shortly after publication of their work, 
who had conceived and planned the 
critical experiments. Gard had the 
proper contacts in Theiler’s laboratory 
to get advice on this priority issue. In a 
brief supplementary review, Gard firmly 
concluded that Theiler was the leading 
scientist in the team and declared his 
work on yellow fever prize-worthy.
Continued deliberations by the Nobel 
committee
In 1948, the Nobel Committee agreed 
with Gard that Theiler’s contributions 
Sven Gard, professor of virology at the 
Karolinska Institutet between 1948 and 
1972. Photo provided by the Karolinska 
Institutet.
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were prize-worthy. But the prize that 
year was instead awarded to Paul H. 
Müller “for his discovery of the high 
efficiency of DDT as a contact poison 
against several arthropods.” Theiler’s 
next nomination was in 1950. This time, 
Antonia Salvat Navarro from Granada, 
Spain, nominated him together with 
another leading yellow fever researcher, 
Wilbur A. Sawyer. Gard, who by that 
time was an adjunct member of the 
Nobel Committee, wrote a two-page 
analysis primarily to define Sawyer’s 
role in vaccine development. Before 
Theiler developed his 17D strain, 
Sawyer and his collaborators tried to 
immunize humans with a previously 
isolated neuroadapted strain of virus 
from mice together with injections of 
human convalescent serum. This pro-
vided some immunity, but the proce-
dure was difficult to control and not 
practically useful. This procedure was 
used, however, to successfully protect 
people working with the virus in the 
laboratory. Gard’s conclusion was that 
Sawyer’s contribution was not of suf-
ficient magnitude and quality to be 
included in a prize for the yellow fever 
vaccine. In its summarizing recom-
mendations to the College of Teachers 
in 1950, the Nobel Committee again 
concluded that Theiler’s work was prize-
worthy. However, the majority of the 
Committee members recommended that 
the prize be given to Philip S. Hench, 
Edward C. Kendall, and Tadeus 
Reichstein “for their discoveries relating 
to the hormones of the adrenal cortex, 
their structure, and biological effects.” 
Still, four of the thirteen members, 
Professors Nils Antoni, Hilding 
  Bergstrand (the chairman), Gard and 
Arne Wallgren, recommended that 
the prize instead be shared by Frank 
MacFarlane Burnet, for his discoveries 
of methods that make cells resistant to 
certain virus infections, and Max Theiler, 
for his discovery of methods to vacci-
nate effectively against yellow fever. 
Burnet was one of the prominent figures 
in the field of virology at the time, but 
he would have to wait until 1960 to get 
his Nobel Prize. The prize Burnet was 
eventually awarded, however, was not 
in virology but in immunology and was 
shared with Peter B. Medawar for their 
discovery of immunological tolerance. 
In 1950, the College of Teachers sup-
ported the majority opinion of the 
committee, and Theiler had to wait one 
more year.
Early on January 31, 1951, the last 
day when prize nominations could be 
submitted for that year, there was no 
proposal of Theiler. But a brief nomi-
nation referring to the evaluations of 
the preceding year was submitted later 
that day by the chairman of the commit-
tee, Vice-Chancellor of the Karolinska 
Institutet and Professor of Pathology 
Hilding Bergstrand. Such a last-minute 
nomination is not unprecedented in 
the Nobel Committee work, but it is 
generally given by the committee’s 
secretary.
Bergstrand not only made the 
“moonlight” nomination of Theiler, 
he was also, somewhat surprisingly, the 
one who performed the evaluation. In 
the beginning of his four-page review, 
he declared that he did not have any-
thing to add to Gard’s description of 
the process of developing the yellow 
fever vaccine. Instead, he highlighted 
the importance of the availability of 
the vaccine, stating that it was the 
practical results that should give Theiler 
an advantage in the competition with 
other candidates for the 1951 prize. 
He also expressed the hope that Theiler’s 
success would serve as an encourage-
ment to other scientists trying to de-
velop vaccines against important human 
virus infections.
In the report to the faculty, all but 
two of the committee members (Gard 
was not included that year) agreed 
with the recommendation that Theiler 
should be awarded the 1951 prize. 
The two dissenters recommended that 
it be given to Selman A. Waksman, 
but this did not happen until the fol-
lowing year when he was awarded the 
prize “for his discovery of streptomy-
cin, the first antibiotic effective against 
tuberculosis.” In 1951, the college of 
teachers agreed with the majority of 
the Committee and awarded Theiler 
the prize.
Theiler received his Nobel Prize 
based on only three nominations (the 
early 1937 nomination did not con-
cern the creation of the 17D strain 
vaccine). By contrast, Waksman had 
accumulated 39 nominations over six 
years before winning the prize. Out 
of the three nominations Theiler re-
ceived, only the one in 1948 was de-
tailed. Thus, Theiler owes special 
thanks to Sabin, who submitted this 
qualified proposal. These two scien-
tists must have met many times in the 
late 1930s when they were working 
at the Rockefeller Institute of Medi-
cal Research and had the same dining 
room privileges. But it seems less 
than likely that they developed a 
close friendship. It is hard to imagine 
two more diametrically different 
personalities.
What is a discovery?
Nobel made some interesting and im-
portant distinctions when he specified 
the three prizes in natural sciences in 
his last will. For physics, he specified 
that the award be given for “a discov-
ery or an invention”; for chemistry, 
Hilding Bergstrand, professor of gen-
eral pathology and pathological anatomy 
1924–1952, vice-chancellor (rector) of the 
Karolinska Institutet 1942–1952, and chair-
man of the Nobel Committee for Physiology 
or Medicine 1947–1952. Photo provided by 
the Karolinska Institutet.
He showed a capacity for a systematized 
approach and persistence in action—
personal qualities that are essential to 
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“a discovery or an improvement”; 
but for medicine or physiology, he 
stated exclusively, “a discovery.” By 
definition, therefore, all prizes in physi-
ology or medicine that have been 
given reflect the identification of a 
discovery. But how can the concept 
of “discovery” be defined and distin-
guished from more consequential and 
applied contributions? And again, 
why has only one of the many viral 
vaccines been recognized, considering 
their enormous humanitarian impact, 
which is truly in accordance with 
Nobel’s specification “to be of benefit 
to mankind”?
This question was answered in part 
in a recent article (29) discussing the 
award of the 1954 Nobel Prize in 
Physiology or Medicine to John Enders, 
Thomas Weller, and Frederick Robbins. 
These researchers demonstrated that 
poliovirus could grow in nonnervous 
tissue, thereby refuting the persistent 
and incorrect dogma that the virus was 
strictly neurotropic. This unexpected 
discovery spearheaded the subsequent 
isolation of many important human 
viral pathogens and paved the way for 
the development of effective vaccines. 
The important contributions of Salk, 
Sabin, and others in the development 
of the polio vaccine can be speculated 
to have been considered derivative, as 
no additional discovery was needed, 
and thus not prize-worthy. Why, then, 
was Theiler’s contribution considered 
a discovery?
In Gard’s preliminary investigation 
in 1948 there are some—in my opinion 
surprisingly harsh—comments on this 
matter. It reads:
“Theiler can not be said to have 
been pioneering. He has not enriched 
the field of virus research with any new 
and epoch-making methods or pre-
sented principally new solutions to the 
problems, but he has shown an excep-
tional capacity to grasp the essentials of 
the observations, his own and others, 
and with safe intuition follow the path 
that led to the goal. The practical im-
portance of Theiler’s work needs not to 
be discussed. It is to a large part thanks 
to him that the worst scourge of the 
tropical belt has now been rendered 
harmless.”
In a milder form, Bergstrand re-
turned to this issue toward the end of 
his laudatory speech delivered at the 
prize ceremony (30):
“The significance of Max Theiler’s 
discovery must be considered to be 
very great from the practical point of 
view, as effective protection against 
yellow fever is one condition for the 
development of the tropical regions—
an important problem in an overpopu-
lated world. Dr. Theiler’s discovery 
does not imply anything fundamentally 
new, for the idea of inoculation against 
a disease by the use of a variant of the 
etiological agent which, though harm-
less, produces immunity, is more than 
150 years old.”
One may ask whether the expression 
“discovery does not imply anything 
fundamentally new” is a contradiction 
in terms.
The problem Theiler faced was 
clearly defined; a live vaccine needed 
to be developed. But which approach 
should be taken? How useful were the 
available techniques and what was the 
need to develop new ones? Theiler 
was good at adapting existing tech-
niques and pioneering the develop-
ment of new approaches. His mouse 
encephalitis model, which later came 
to be widely applied in virology, and 
his modifications of the crude tissue 
culture techniques of the day are ex-
amples of this. His idea of growing the 
virus for hundreds of passages in chick 
embryo cultures with and without 
brain material was ingenious. In the 
critical tissue culture experiments, he 
showed a capacity for a systematized 
approach and persistence in action—
personal qualities that are essential to 
good science. The experimental sys-
tems he used were highly complex, 
and hence the outcomes of the experi-
ments were unpredictable. Here, both 
his intuition and his capacity to appre-
ciate the relative significance of the 
many different observations he made 
came into play.
But one ingredient was still needed 
for Theiler to reach his goal. That in-
gredient was luck. Louis Pasteur’s famous 
dictum, “in the field of observation, 
chance only favors the prepared mind,” 
promptly comes to mind. Theiler was 
lucky that passage of the Asibi strain in 
chick embryos without central nervous 
systems suddenly changed its nature 
and lost both its viscerotropic and neu-
rotropic properties, but still retained its 
capacity to replicate and induce an 
immune response. It was also fortunate 
that the properties of the attenuated virus 
turned out to be stable. It was the ful-
filment of all these conditions that 
  allowed Theiler to make what must be 
concluded to be a true discovery.
To conclude, it would of course 
be of considerable interest to learn 
what Theiler himself thought about 
his contribution and the fact that it 
was recognized by a Nobel Prize. 
Some insight into this can be gained 
from the interview conducted by Dr. 
Harriet Zuckerman (31), the author 
of a book on American Nobel laure-
ates (32). Discussing the conditions 
for good science, Theiler emphasized 
the role of a hunch and also of luck. 
Being a man of paradoxes, he com-
mented on his achievements in two 
contradictory ways. On the one hand, 
he stated that he had not done any-
thing fundamental and that he did not 
Max Theiler. Photo provided by the Nobel 
Foundation.
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have any background for making es-
sential theoretical contributions. On 
the other hand, he made it clear that 
it was he alone who took the essential 
initiatives to the experiments that led to 
the development of the vaccine. In his 
view, if anyone should get a credit for 
the vaccine it should be him and him 
alone. No one else needed to be in-
cluded. Thus, although he was not a 
man to boast of his own achievements, 
he probably, in his humble way, knew 
his worth.
It may be appropriate to let Theiler 
himself have the last word. In his speech 
at the prize award banquet, he used 
the  following generous and gracious 
formulations (33):
“I like to feel that in honouring 
me you are honouring all the workers 
in the laboratory, field and jungle 
who have contributed so much, often 
under conditions of hardship and 
danger, to our understanding of this 
disease. I would also like to feel that 
you are honouring those who gave 
their lives in gaining knowledge 
which was of inestimable value. They 
were truly martyrs of science, who 
died that others might live. And, finally, 
I would like to feel that in honouring 
me you are honouring The Rockefeller 
Foundation under whose auspices 
most of the modern work on yellow 
fever has been done—a gesture from 
one great foundation to another—
both having the ideal of benefiting 
mankind throughout the world. 
Thank you.”
The access to the Archives of the Nobel 
Committee for Physiology or Medicine of the 
Karolinska Institutet, the Rockefeller Archive 
Center, the Library of The American Philosophical 
Society, and a transcript of an interview with 
M. Theiler by Harriett Zuckerman at Columbia 
University Oral History Office are gratefully 
acknowledged.
Darwin Stapleton kindly edited the language. 
Baruch Blumberg, Günther Blobel, Purnell Choppin, 
Sam Katz, Jan Lindsten, Rolf Luft, Erik Lycke, and 
Stanley Prusiner read the manuscript and gave valu-
able advice.
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